Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Access Program for AM0010 (Pegilodecakin) Subcutaneous Injection

NCT03554434 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03554434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03554434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Access Program for AM0010 (Pegilodecakin) Subcutaneous Injection
Lead sponsor
Eli Lilly and Company
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal carcinoma, melanoma, non-small cell lung carcinoma, ovarian cancer, pancreatic carcinoma, prostate cancer, renal cell carcinoma, solid tumors